Clinical Trial Update: Impact of 2.0g Daily of MAG-EPA on the AA/EPA Ratio and Inflammation Biomarkers in a Healthy Population Aged of 50+. [Phase 4]

View source ↗

Summary

Phase 4 clinical trial updating the impact of 2.0 g daily MAG-EPA on the AA/EPA ratio and inflammation biomarkers in adults 50+.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammation

Drugs mentioned

• MAG-EPA (MAG-ethyl polyunsaturated fatty acid? (MAG-EPA) clarifications not provided)

Snippet

Sponsor: SCF Pharma | Conditions: Inflammation | Phase 4 | Status: COMPLETED